Trevi Therapeutics, Inc. TRVI
14.82 USD -0.10 (-0.64%)
At closeNov 11, 2026, 4:20 PM EST
14.82 0.00 0.00%
After hours · Nov 11, 4:20 PM ET
14.48 Day range 15.12
9.82 52-week range 20.22
- YTD
- +18.33%
- 1 year
- +22.44%
News
seekingalpha.com Trevi Therapeutics, Inc. (TRVI) Q3 2026 Earnings Call Transcript Trevi Therapeutics, Inc. (TRVI) Q3 2026 Earnings Call Transcript
marketbeat.com What Trevi Therapeutics (TRVI) Said on Its Q3 Earnings Call Trevi Therapeutics NASDAQ: TRVI said it remains on track to report results from its lead chronic cough trials in 2027 and 2028, while preparing a new study in patients with interstitial lung disease…
benzinga.com Trevi Therapeutics Q3 2026 Earnings Call Transcript Trevi Therapeutics (NASDAQ:TRVI) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com Trevi Therapeutics Q3 EPS $(0.13), Inline Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.13) per share which met the analyst consensus estimate. This is a 62.5 percent decrease over losses of $(0.08) per share from the…
globenewswire.com Trevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates Initiated Phase 3 OCEAN-2 trial for patients with IPF-related chronic cough in the third quarter; both Phase 3 OCEAN trials actively recruiting Positive meeting with the FDA on the non-IPF…
globenewswire.com Trevi Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 9, 2026 NEW HAVEN, Conn., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral…
globenewswire.com Trevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference Fireside chat with management on Wednesday, November 11, 2026, at 10:00 a.m. ET Fireside chat with management on Wednesday, November 11, 2026, at 10:00 a.m. ET
benzinga.com Trevi Therapeutics Announces Results From Phase 2b CORAL Trial Accepted As Oral Presentation At CHEST 2026 Annual Meeting Of American College Of Chest Physicians Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients with…
globenewswire.com Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual Meeting Professor Philip Molyneaux will present on the patient-reported outcomes from the Phase 2b CORAL trial of nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary…
benzinga.com Trevi Therapeutics Q2 2026 Earnings Call Transcript Trevi Therapeutics (NASDAQ:TRVI) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For…
seekingalpha.com Trevi Therapeutics, Inc. (TRVI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Trevi Therapeutics, Inc. (TRVI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
globenewswire.com Trevi Therapeutics to Participate in Upcoming September Conferences NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral…
globenewswire.com Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026 Professor Marlies Wijsenbeek will give an oral presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with…
seekingalpha.com Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform Trevi Therapeutics leverages Haduvio's dual mechanism to target IPF-related chronic cough, with expansion plans into non-IPF ILD and refractory chronic cough. Haduvio's positive Phase II data in both…
benzinga.com Jones Trading Maintains Buy on Trevi Therapeutics, Raises Price Target to $28 Jones Trading analyst Debanjana Chatterjee maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $24 to $28.
marketbeat.com Trevi Therapeutics Q2 Earnings Call Highlights Trevi Therapeutics NASDAQ: TRVI said it began two clinical trials during the second quarter and plans to launch a third study in the third quarter as it advances nalbuphine ER, also known as Haduvio,…- benzinga.com Oppenheimer Maintains Outperform on Trevi Therapeutics, Raises Price Target to $25 Oppenheimer analyst Leland Gershell maintains Trevi Therapeutics (NASDAQ:TRVI) with a Outperform and raises the price target from $24 to $25.
benzinga.com Cantor Fitzgerald Maintains Overweight on Trevi Therapeutics, Raises Price Target to $30 Cantor Fitzgerald analyst Josh Schimmer maintains Trevi Therapeutics (NASDAQ:TRVI) with a Overweight and raises the price target from $25 to $30.
seekingalpha.com Trevi Therapeutics, Inc. (TRVI) Q2 2026 Earnings Call Transcript Trevi Therapeutics, Inc. (TRVI) Q2 2026 Earnings Call Transcript- benzinga.com Trevi Therapeutics Q2 EPS $(0.11), Inline Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is a 22.22 percent decrease over losses of $(0.09) per share from the…
globenewswire.com Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in the third quarter of 2026
globenewswire.com Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026 NEW HAVEN, Conn., July 30, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral…
globenewswire.com Trevi Therapeutics to Participate in Upcoming August Conferences NEW HAVEN, Conn. , July 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral…
benzinga.com This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday Wall Street analysts upgraded Fortinet, Goldman Sachs, Adaptive Biotechnologies, and Five Below, with positive outlooks and raised price targets.
benzinga.com This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Top Wall Street analysts change outlook on top stocks. For analyst rating changes, see https://www.benzinga.com/analyst-stock-ratings. INSM initiated with $192 PT.
benzinga.com BMO Capital Initiates Coverage On Trevi Therapeutics with Outperform Rating, Announces Price Target of $36 BMO Capital analyst Connor Murphy initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Outperform rating and announces Price Target of $36.
benzinga.com B. Riley Securities Maintains Buy on Trevi Therapeutics, Raises Price Target to $31 B. Riley Securities analyst Mayank Mamtani maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $21 to $31.
benzinga.com Global Payments To Rally More Than 28%? Here Are 10 Top Analyst Forecasts For Monday Wall Street analysts change ratings for FITB, TRVI, JAZZ, GPN, EAT, URBN, MNST. See full list on benzinga.com/analyst-stock-ratings- benzinga.com HC Wainwright & Co. Maintains Buy on Trevi Therapeutics, Raises Price Target to $24 HC Wainwright & Co. analyst Brandon Folkes maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $21 to $24.
benzinga.com ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On Friday US stocks lower, Nasdaq falls 400 pts. ManpowerGroup shares rise after upbeat earnings. Other big gainers: PHOE, SG, TRVI, DCBO, ZNTL, GPRE, SLS, FEIM, TRV, BHVN, KOS, BJRI, MBX.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers NextCure (NASDAQ:NXTC) shares rose 305.5% to $8.84 during Tuesday's pre-market session. The market value of their outstanding shares is at $7.8 million. Shuttle Pharmaceuticals (NASDAQ:SHPH)…
globenewswire.com Trevi Therapeutics Announces Upcoming June and July Event Schedule NEW HAVEN, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral…
fool.com Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases.
benzinga.com Needham Reiterates Buy on Trevi Therapeutics, Maintains $23 Price Target Needham analyst Serge Belanger reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $23 price target.
seekingalpha.com Trevi Therapeutics, Inc. (TRVI) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript Trevi Therapeutics, Inc. (TRVI) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
marketbeat.com Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030 Trevi Therapeutics NASDAQ: TRVI outlined plans to advance Haduvio, its extended-release formulation of nalbuphine, across multiple chronic cough indications, with management emphasizing upcoming…- benzinga.com HC Wainwright & Co. Reiterates Buy on Trevi Therapeutics, Maintains $21 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $21 price target.
- benzinga.com Needham Maintains Buy on Trevi Therapeutics, Lowers Price Target to $23 Needham analyst Serge Belanger maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and lowers the price target from $24 to $23.
- benzinga.com Trevi Therapeutics Q1 2026 Earnings Call Transcript
- benzinga.com Trevi Therapeutics Q1 EPS $(0.09) Misses $(0.07) Estimate Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.07) by 28.57 percent. This is unchanged from the same period last…
benzinga.com Earnings Scheduled For May 5, 2026 - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com What's Going On With Trevi Therapeutics Stock? Trevi Therapeutics shares are trading higher after it announced pricing of its $150 million offering of 11.6 million shares at $13 per share.
benzinga.com Netflix, Trevi Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session US stock futures rise, Dow up by 250 pts. Netflix shares fall 9.6% after weak forecast & Reed Hastings' departure. Other stocks also dip in pre-market.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com Why Blaize Holdings Shares Are Trading Higher By 24%; Here Are 20 Stocks Moving Premarket Blaize Holdings rose 24.3% in pre-market trading on $50M contract with NeoTensr & MOU with Winmate for edge AI deployments. Other gainers & losers.- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com Trevi Therapeutics Commences $150M Common Stock Offering Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients…
benzinga.com These Analysts Revise Their Forecasts On Trevi Therapeutics Following Q4 Earnings Trevi Therapeutics reported a smaller loss in Q4, beating analyst estimates. Share price fell 2.5%. Analysts have mixed opinions on buying TRVI stock.- benzinga.com Morgan Stanley Maintains Overweight on Trevi Therapeutics, Lowers Price Target to $18 Morgan Stanley analyst Judah Frommer maintains Trevi Therapeutics (NASDAQ:TRVI) with a Overweight and lowers the price target from $19 to $18.